Acute rejection, steroid resistant/antibody treated As reported in the articles · patients with kidney transplant recipients
Mycophenolate mofetil (MMF) leads to lower acute rejection, steroid resistant/antibody treated As reported in… compared with azathioprine (AZA) (high certainty).
1 finding from 1 review
Erythrocyte alloantibody formation Laboratory assessment · women with postpartum iron deficiency anaemia
It is very uncertain whether red blood cell transfusion changes erythrocyte alloantibody formation Laboratory assessment compared with non‐transfusion (Comparison 2) (very low certainty).
1 finding from 1 review
Hepatitis B antibody titre (IgG) · people living with HIV
1 finding from 1 review
Immunogenicity: Adequate antibody response (NT ≥1:10), · adults with HIV infection
Immunologic response to YF vaccine in HIV‐infected adults before HIV… may leads to lower immunogenicity: Adequate antibody response (NT ≥1:10), compared with immunologic response to YF vaccine (low certainty).
1 finding from 1 review
Immunogenicity: Adequate antibody response (NT ≥1:10), · Children with HIV infection
It is very uncertain whether immunologic response to YF vaccine in HIV‐infected children changes adequate antibody response (NT ≥1:10), compared with immunologic response to YF vaccine (very low certainty).
1 finding from 1 review
Immunogenicity: Adequate antibody response (NT ≥1:10), · adults with HIV infection
It is very uncertain whether immunologic response to YF vaccine in HIV‐infected adults changes immunogenicity: Adequate antibody response (NT ≥1:10), compared with immunologic response to YF vaccine (very low certainty).
1 finding from 1 review
Duration: Adequate antibody response (NT ≥1:10), · adults with HIV infection
It is very uncertain whether immunologic response to YF vaccine in HIV‐infected adults changes duration: Adequate antibody response (NT ≥1:10), compared with immunologic response to YF vaccine (very low certainty).
1 finding from 1 review
Intervention not reported
HCV antibody vs. placebo · patients undergoing liver transplantation for chronic hepatitis C viral infection.
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
HCV antibody vs. placebo · patients undergoing liver transplantation for chronic hepatitis C viral infection.
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality Mortality at latest · heart transplant recipients
Interleukin‐2 RA induction showed no clear difference in mortality Mortality at latest compared with monoclonal antibody induction (low certainty).
1 finding from 1 review
Acute rejection Acute rejection grade 3A or more verified by biopsy · heart transplant recipients
Interleukin‐2 RA induction showed no clear difference in acute rejection Acute rejection grade 3A or more verified by biopsy compared with monoclonal antibody induction (low certainty).
1 finding from 1 review
Infection Number of participants diagnosed with infection · heart transplant recipients
Interleukin‐2 RA induction showed no clear difference in infection Number of participants diagnosed with infection compared with monoclonal antibody induction (low certainty).
1 finding from 1 review
CMV infection · heart transplant recipients
Interleukin‐2 RA induction showed no clear difference in cytomegalovirus infection Number of participants diagnosed with CMV… compared with monoclonal antibody induction (low certainty).
1 finding from 1 review
Post‐transplantation lymphoproliferative disorder Number of participants diagnosed with PTLD · heart transplant recipients
Interleukin‐2 RA induction showed no clear difference in post‐transplantation lymphoproliferative disorder Number of… compared with monoclonal antibody induction (low certainty).
1 finding from 1 review
Cancer · heart transplant recipients
Interleukin‐2 RA induction showed no clear difference in cancer Number of participants diagnosed with cancer compared with monoclonal antibody induction (low certainty).
1 finding from 1 review
Mortality Mortality at latest · heart transplant recipients
Interleukin‐2 RA showed no clear difference in mortality Mortality at latest compared with polyclonal antibody induction (low certainty).
1 finding from 1 review
Acute rejection Acute rejection grade 3A or more verified by biopsy · heart transplant recipients
Interleukin‐2 RA may leads to higher acute rejection Acute rejection grade 3A or more verified by biopsy compared with polyclonal antibody induction (low certainty).
1 finding from 1 review
Infection Number of participants diagnosed with infection · heart transplant recipients
Interleukin‐2 RA showed no clear difference in infection Number of participants diagnosed with infection compared with polyclonal antibody induction (low certainty).
1 finding from 1 review
CMV infection · heart transplant recipients
Interleukin‐2 RA showed no clear difference in cytomegalovirus infection Number of participants diagnosed with CMV… compared with polyclonal antibody induction (low certainty).
1 finding from 1 review
Post‐transplantation lymphoproliferative disorder Number of participants diagnosed with PTLD · heart transplant recipients
1 finding from 1 review